title: Activation of 5-HT1B receptors inhibits the vasodepressor sensory CGRPergic outflow in pithed rats.
abstract: The importance of calcitonin gene-related peptide (CGRP) in the regulation of vascular tone has been widely documented. Indeed, stimulation of the perivascular sensory outflow in pithed rats results in vasodepressor responses, which are mediated by CGRP release. These vasodepressor responses are inhibited by clonidine via prejunctional alpha(2A/2C)-adrenoceptors, but no study has yet reported the role of prejunctional 5-hydroxytryptamine (5-HT) receptors in this experimental model. Since activation of prejunctional 5-HT(1) receptors results in inhibition of neurotransmitter release, this study sets out to investigate as an initial approach the role of 5-HT(1B) receptors in the inhibition of the vasodepressor sensory outflow in pithed rats. Male Wistar pithed rats were pretreated with hexamethonium (2mg/kg.min) followed by i.v. continuous infusions of methoxamine (20 microg/kg min), and then by saline (0.02 ml/min) or CP-93,129 (a rodent 5-HT(1B) receptor agonist; 0.1, 1 and 10 microg/kg min). Under these conditions, electrical stimulation (0.56-5.6 Hz; 50 V and 2 ms) of the spinal cord (T(9)-T(12)) resulted in frequency-dependent decreases in diastolic blood pressure. The infusions of CP-93,129, as compared to those of saline, inhibited the vasodepressor responses induced by electrical stimulation without affecting those to i.v. bolus injections of exogenous alpha-CGRP (0.1, 0.18, 0.31, 0.56 and 1 microg/kg). This inhibition by CP-93,129 was abolished by the antagonists GR127935 (5-HT(1B/1D)) or SB224289 (5-HT(1B)), but not by BRL15572 (5-HT(1D)). The above results suggest that CP-93,129-induced inhibition of the vasodepressor (perivascular) sensory outflow in pithed rats is mainly mediated by activation of prejunctional 5-HT(1B) receptors.
authors.affiliation: Departamento de Farmacobiología, Cinvestav-Coapa, Col. Granjas-Coapa, Tlalpan, México DF, Mexico.
authors.forename: Abimael
authors.initials: A
authors.lastname: González-Hernández
authors.forename: Enriqueta
authors.initials: E
authors.lastname: Muñoz-Islas
authors.forename: Jair
authors.initials: J
authors.lastname: Lozano-Cuenca
authors.forename: Martha B
authors.initials: MB
authors.lastname: Ramírez-Rosas
authors.forename: Araceli
authors.initials: A
authors.lastname: Sánchez-López
authors.forename: David
authors.initials: D
authors.lastname: Centurión
authors.forename: Eduardo
authors.initials: E
authors.lastname: Ramírez-San Juan
authors.forename: Carlos M
authors.initials: CM
authors.lastname: Villalón
mesh_terms: D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D015740:Calcitonin Gene-Related Peptide / Q000378:metabolism* / Q000494:pharmacology; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D004558:Electric Stimulation; D006339:Heart Rate / Q000187:drug effects; D018738:Hexamethonium / Q000494:pharmacology; D007262:Infusions, Intravenous; D008297:Male; D008729:Methoxamine / Q000494:pharmacology; D010881:Piperidones / Q000494:pharmacology; D011725:Pyridines / Q000494:pharmacology; D011758:Pyrroles / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D044302:Receptor, Serotonin, 5-HT1B / Q000378:metabolism; D058825:Serotonin 5-HT1 Receptor Agonists; D017366:Serotonin Receptor Agonists / Q000494:pharmacology; D012965:Sodium Chloride / Q000494:pharmacology; D013116:Spinal Cord; D013141:Spiro Compounds / Q000494:pharmacology; D013997:Time Factors; D014662:Vasoconstrictor Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D010881:Piperidones; D011725:Pyridines; D011758:Pyrroles; D044302:Receptor, Serotonin, 5-HT1B; C108518:SB 22489G; D058825:Serotonin 5-HT1 Receptor Agonists; D017366:Serotonin Receptor Agonists; D013141:Spiro Compounds; D014662:Vasoconstrictor Agents; C065046:3-(1,2,5,6-tetrahydropyrid-4-yl)pyrrolo(3,2-b)pyrid-5-one; D018738:Hexamethonium; D012965:Sodium Chloride; D008729:Methoxamine; D015740:Calcitonin Gene-Related Peptide